Oruka Therapeutics (ORKA) Price & Analysis

Compare

619 Followers

ORKA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.49 - $52.32

Previous CloseN/A

Volume71.58K

Average Volume (3M)281.94K

Market Cap

$509.19M

Enterprise Value$82.42M

Total Cash (Recent Filing)$349.09M

Total Debt (Recent Filing)$947.00K

Price to Earnings (P/E)―

Beta0.88

Next Earnings

Jul 31, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Aug 29, 2024

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding37,440,510

10 Day Avg. Volume116,547

30 Day Avg. Volume281,942

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.16

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-2.58K

Enterprise Value/Ebitda-1.10

Forecast

1Y Price Target

$43.40

Price Target Upside203.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Market PotentialORKA-002 is positioned to potentially become a strong competitor to existing treatments, which could significantly enhance Oruka's market presence.

Regulatory ApprovalThe FDA has cleared Oruka's Investigational New Drug application for its Phase 2a trial of ORKA-001, a promising step in developing a treatment for moderate-to-severe psoriasis.

Bears Say

Market RecognitionThe market significantly underappreciates the potential for Oruka to reshape the psoriasis treatment paradigm with their long-acting mAbs, ORKA-001 and ORKA-002.

ValuationORKA-002 remains massively underrated, with multiple near- and medium-term value inflection points.

Oruka Therapeutics News

Oruka Therapeutics announces IND clearance for EVERLAST-A Phase 2a trial

Oruka Therapeutics (ORKA) announced that the U.S. FDA cleared its investigational new drug, IND, application for its Phase...

15d ago

ORKA

Oruka Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Oruka Therapeutics today and set a price target...

13d ago

ORKA

Strong Buy Recommendation for Oruka Therapeutics: Promising Pipeline and Attractive Valuation

Leerink Partners analyst David Risinger has reiterated their bullish stance on ORKA stock, giving a Buy rating on...

13d ago

ORKA

Positive Outlook for Oruka Therapeutics: ORKA-001’s Promising Phase 2a Trial and Potential Market Differentiation

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Oruka Therapeutics, with a...

14d ago

ORKA

Oruka Therapeutics: A Promising Contender in the $30 Billion Psoriasis Market with Innovative Treatments ORKA-001 and ORKA-002

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Oruka Therapeutics, retaining the price target of...

20d ago

ORKA

Oruka Therapeutics Appoints New Chief Operating Officer

Oruka Therapeutics ( ($ORKA) ) has provided an update. On July 1, 2025, Oruka Therapeutics appointed Laura Sandler...

1M ago

ORKA

Oruka Therapeutics Holds Annual Stockholders Meeting

An announcement from Oruka Therapeutics ( ($ORKA) ) is now available. On June 2, 2025, Oruka Therapeutics, Inc....

2M ago

ORKA

Oruka Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics (ORKA...

2M ago

ORKA

Oruka Therapeutics initiated with a Buy at BTIG

BTIG initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $44 price target The firm, which...

3M ago

ORKA

Buy Rating for Oruka Therapeutics: Promising Pipeline and Strong Financial Position

Analyst David Risinger of Leerink Partners maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report), retaining...

3M ago

ORKA

Oruka Therapeutics: Strong Financial Position and Promising Clinical Developments Support Buy Rating

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and...

3M ago

ORKA

Oruka Therapeutics reports Q1 EPS (40c), consensus (47c)

“We are thrilled with the continued rapid progress we are making to advance our co-lead programs, which we...

3M ago

ORKA

Oruka Therapeutics’ ORKA-001: Promising Developments and Buy Rating Justification

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics (ORKA – Research Report), retaining...

3M ago

ORKA

Oruka Therapeutics announces preclinical data for ORKA-002

Oruka Therapeutics (ORKA) announced new preclinical data on ORKA-002, a novel extended half-life monoclonal antibody targeting IL-17A/F, from...

5M ago

ORKA

ORKA FAQ

What was Oruka Therapeutics’s price range in the past 12 months?

Oruka Therapeutics lowest stock price was $5.49 and its highest was $52.32 in the past 12 months.

What is Oruka Therapeutics’s market cap?

Oruka Therapeutics’s market cap is $509.19M.

When is Oruka Therapeutics’s upcoming earnings report date?

Oruka Therapeutics’s upcoming earnings report date is Jul 31, 2025 which is 5 days ago.

How were Oruka Therapeutics’s earnings last quarter?

Oruka Therapeutics released its earnings results on May 14, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.508 by $0.108.

Is Oruka Therapeutics overvalued?

According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oruka Therapeutics pay dividends?

Oruka Therapeutics pays a Notavailable dividend of $19.356 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics dividends here

What is Oruka Therapeutics’s EPS estimate?

Oruka Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oruka Therapeutics have?

Oruka Therapeutics has 37,440,510 shares outstanding.

What happened to Oruka Therapeutics’s price movement after its last earnings report?

Oruka Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.508. Following the earnings report the stock price went down -1.45%.

Which hedge fund is a major shareholder of Oruka Therapeutics?

Currently, no hedge funds are holding shares in ORKA

Oruka Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-39.06%

Trailing 12-Months

Asset Growth

927.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics (ORKA) Earnings & Revenues

ORKA Earnings Data >

ORKA Stock 12 Month Forecast

Average Price Target

$43.40

▲(203.50%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","18":"$18","28":"$28","38":"$38","48":"$48"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,18,28,38,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.8,14.50769230769231,17.215384615384615,19.923076923076923,22.630769230769232,25.33846153846154,28.046153846153846,30.753846153846155,33.46153846153847,36.16923076923077,38.87692307692308,41.58461538461539,44.29230769230769,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.8,14.230769230769232,16.661538461538463,19.092307692307692,21.52307692307692,23.953846153846154,26.384615384615383,28.815384615384616,31.246153846153845,33.676923076923075,36.107692307692304,38.53846153846153,40.96923076923076,{"y":43.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.8,13.96923076923077,16.138461538461538,18.307692307692307,20.47692307692308,22.646153846153844,24.815384615384616,26.984615384615385,29.153846153846153,31.323076923076922,33.49230769230769,35.661538461538456,37.830769230769235,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.52,"date":1556668800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.52,"date":1580515200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >